<DOC>
	<DOC>NCT01131559</DOC>
	<brief_summary>The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.</brief_summary>
	<brief_title>Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Subjects will meet DSMIVTR criteria bipolar I or II disorder, Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>manic depression</keyword>
	<keyword>depression</keyword>
	<keyword>Bipolar I or II</keyword>
</DOC>